Sergio Cifuentes Canaval, Medical Oncologist at Las Américas Auna Clinic, shared a post on X about a paper by Icro Meattini et al published in The Breast:
“New real-world evidence on combining radiotherapy with T-DXd in metastatic breast cancer.
A multicenter retrospective study (n=147) published in The Breast evaluated the safety of concomitant trastuzumab deruxtecan (T-DXd) and radiation therapy (RT) in HER2+ and HER2-low metastatic breast cancer.
Key safety findings:
- ILD/pneumonitis (any grade): 10.4% with RT vs 8.8% without RT.
- Grade ≥3 ILD: 6.0% with RT vs 2.5% without RT.
- No significant increase in grade ≥3 overall AEs (11.9% vs 20.0%, p=0.30).
- Permanent T-DXd discontinuation similar between groups (~12–14%).
- One symptomatic radionecrosis reported (1.5%) after brain RT.
- No significant increase in grade ≥3 adverse events with RT + T-DXd vs. T-DXd alone (11.9% vs 20.0%, p=0.30).
- Similar rates of permanent T-DXd discontinuation (11.9% vs 13.8%).
- One case of symptomatic radionecrosis (1.5%) after intracranial RT.
- No negative impact on progression-free or overall survival.
Most common RT site: CNS (54.9%) — crucial for managing brain metastases.
Takeaway: Concomitant T-DXd and RT appears feasible and well-tolerated in real-world practice, supporting combined modality strategies in selected patients.”
Title: Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort.
Authors: Luca Visania, Ivica Ratosa, Rupert Bartsch, Barbro Linderholm, Gaia Griguolo, Calogero Saieva, Carlotta Becherini, Marianna Valzano, Viola Salvestrini, Angelika M. Starzer, Peter Kush, Niccolò Bertini, Andrea Rampini, Chiara Mattioli, Domen Ribnikar, Jacopo Nori Cucchiari, Lorenzo Orzalesi, Simonetta Bianchi, Matteo Lambertini, Valentina Guarneri, Lorenzo Livi, and Icro Meattini.
You can read the full article in The Breast.
More posts about Breast Cancer.